CTOs on the Move

Global Events Partners, Philadelphia

www.gepphilly.com

 
Global Events Partners, Philadelphia is a Philadelphia, PA-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.gepphilly.com
  • 1600 Arch St Ste 200
    Philadelphia, PA USA 19103
  • Phone: 267.514.2620

Executives

Name Title Contact Details

Similar Companies

Norwalk-nagarote Sister City Project

Norwalk-nagarote Sister City Project is a Norwalk, CT-based company in the Business Services sector.

Braithwaite Communications

Braithwaite Communications is a Philadelphia, PA-based company in the Business Services sector.

Institute for International Research - USA

Institute for International Research - USA is one of the leading companies in Business Services industry. Institute for International Research - USA is based in New York, NY. You can find more information on Institute for International Research - USA at www.iirusa.com

US Translation Company

U.S. Translation Company offers precision global communication with white glove service since 1995. With over 4000 language translation and live interpretation professionals we can deliver your message in over 100 languages. We`ve helped businesses large and small reach their goals of selling to an international audience in multiple industries including: engineering, medical device, aerospace, legal, manufacturing and many more!

Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.